C12P 31 - Preparation of compounds containing a five-membered ring having two side-chains in ortho position to each other, and having at least one oxygen atom directly bound to the ring in ortho position to one of the side-chains, one side-chain containing, not directly bound to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having at least one oxygen atom bound in gamma-position to the ring, e.g. prostaglandins

Patents for C12P 31 - Preparation of compounds containing a five-membered ring having two side-chains in ortho position to each other, and having at least one oxygen atom directly bound to the ring in ortho position to one of the side-chains, one side-chain containing, not directly bound to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having at least one oxygen atom bound in gamma-position to the ring, e.g. prostaglandins (92)
09/2014
09/30/2014	US8846958 Process for the preparation of lubiprostone
06/2014
06/03/2014	US8741563 Metronidazole resistance in trichomonas vaginalis and single nucleotide polymorphisms
10/2013
10/01/2013	US8546114 Processes for the preparation of optically active cyclopentenones and cyclopentenones prepared therefrom
06/2012
06/07/2012	US20120142047 Purification and Separation Treatment Assembly (PASTA) for Biological Products
05/2011
05/26/2011	WO2011062584A1 Reducing inflammation using cell therapy
05/26/2011	CA2781194A1 Reducing inflammation using cell therapy
05/11/2011	CN102050812A 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
05/11/2011	CN102050811A 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
05/11/2011	CN102050771A Method for preparing prostaglandin derivative
03/2011
03/16/2011	EP2294209A2 Process for the preparation of prostaglandin f2alpha esters employing a lipase
10/2010
10/28/2010	CA2759244A1 Cell lines that produce prostaglandin f2 alpha (pgf2a) and uses thereof
06/2010
06/03/2010	WO2009147479A3 Process for the preparation of prostaglandin f2alpha esters employing a lipase
12/2009
12/10/2009	WO2009147479A2 Esterification process of prostaglandins and analogues thereof
12/10/2009	CA2724734A1 Esterification process of prostaglandins and analogues thereof
10/2009
10/20/2009	US7605144 Proliferation inhibition of pathological cells; prodrug converted to or releasing cellular toxin
09/2009
09/02/2009	EP1853719B1 Enzymatic transformation of a prostaglandin (bimatoprost) intermediate
08/2009
08/19/2009	CN101511211A Food product comprising a proline specific protease
10/2008
10/15/2008	EP1978829A2 Food product comprising a proline specific protease
09/2008
09/12/2008	WO2007088062A3 Food product comprising a proline specific protease
08/2007
08/09/2007	WO2007088062A2 Food product comprising a proline specific protease
08/09/2007	CA2637701A1 Food product comprising a proline specific protease, the preparation thereof and its use for degrading toxic or allergenic gluten peptides
05/2007
05/15/2007	US7217537 a deletion in the glgA gene in a carotenogenic microbial host cell engineered to recombinantly produce at least one carotenoid compound (Methylomonas sp. and Escherichia coli) resulted in viable mutant cells characterized by a significant increase in carotenoid production
03/2007
03/22/2007	US20070065445 Novel cyclooxygenase variants and methods of use
01/2007
01/30/2007	US7169580 Protein having PGE2 synthase activity and use thereof
12/2006
12/13/2006	EP1731913A2 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
01/2006
01/19/2006	US20060014268 Method for producing highly unsaturated fatty acids and lipid containing same
05/2005
05/25/2005	EP1532242A2 Methods for preparing purified prostaglandin e synthase
03/2005
03/31/2005	WO2003018756A3 Methods for preparing purified prostaglandin e synthase
03/23/2005	CN1194097C Process for preparing prostaglandin El as rau material Of medicines
02/2005
02/16/2005	EP1432811A4 Cell separation matrix
11/2004
11/24/2004	EP1135519A4 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
10/2004
10/14/2004	US20040203045 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
07/2004
07/15/2004	US20040137590 Allene oxide cyclase gene and use thereof for producing jasmonic acid
06/2004
06/30/2004	EP1432811A1 Cell separation matrix
04/2004
04/27/2004	US6727075 Measuring lipid peroxidation in mammals; obtain tissue or fluid sample evaluate the concentration of prostaglandin isomer marker present, compare to control, amplified concentration of the marker indicates oxidative stress
08/2003
08/21/2003	US20030157084 Methods for preparing purified prostaglandin E synthase
05/2003
05/01/2003	CA2463467A1 Cell separation matrix
03/2003
03/06/2003	WO2003018756A2 Methods for preparing purified prostaglandin e synthase
10/2002
10/30/2002	EP1252318A2 Allene oxide cyclase gene and use thereof for producing jasmonic acid
06/2002
06/13/2002	US20020072083 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
03/2002
03/28/2002	WO2001057224A3 Allene oxide cyclase gene and use thereof for producing jasmonic acid
01/2002
01/09/2002	CN1330150A Process for preparing prostaglandin E1 as raw material of medicines
09/2001
09/26/2001	EP1135519A1 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
08/2001
08/23/2001	DE10004468A1 Allenoxidcyclasegen und dessen Verwendung zum Herstellen von Jasmonsäure Allenoxidcyclasegen and its use for the production of jasmonic acid
08/09/2001	WO2001057224A2 Allene oxide cyclase gene and use thereof for producing jasmonic acid
04/2001
04/05/2001	WO2000032805A9 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
06/2000
06/08/2000	WO2000032805A1 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
06/08/2000	CA2353795A1 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
05/1998
05/20/1998	CN1182136A Production technology of material medicine for prostaglandin E1
10/1997
10/01/1997	CN1160766A Prostaglandin E1 medicine material and its production technology
04/1995
04/04/1995	US5403724 Treating with a culture of Candida solani and isolating the 15-alpha hydroxyprostaglandin intermediate
09/1992
09/02/1992	CN1064105A Fixed zymological method for production of prostaglandin e*
07/1991
07/03/1991	EP0262126B1 Microbiological reduction of intermediary products of prostacyclin with a 15-ketonic group
05/1991
05/02/1991	EP0424915A2 Methods for producing prostaglandins and for purifying the same
04/1989
04/25/1989	CA1253100A1 Microbiological reduction of prostacyclin intermediates with a 15-keto group
04/1988
04/06/1988	EP0262126A1 Microbiological reduction of intermediary products of prostacyclin with a 15-ketonic group.
12/1987
12/08/1987	US4711842 Fusing macrophage tumor cell line with non-tumor macrophage; interleukin-1 produced
12/1986
12/04/1986	WO1986007092A1 Microbiological reduction of intermediary products of prostacyclin with a 15-ketonic group
02/1986
02/26/1986	EP0172233A1 Punaglandins and pharmaceutical use thereof
08/1985
08/29/1985	WO1985003706A1 Punaglandins and pharmaceutical use thereof
09/1984
09/19/1984	EP0118917A2 Method for production of biologically active substances
08/1984
08/07/1984	CA1172192A1 16-amino-prostaglandin derivatives, their acid addition salts and a process for the preparation thereof
03/1983
03/09/1983	EP0073397A1 Enol acylate analogs of E1 and E2 prostaglandins
02/1983
02/08/1983	US4372973 Abortive or oxytocic agents
12/1982
12/14/1982	US4363817 Enol acylate analogs of E1 and E2 prostaglandins
01/1981
01/27/1981	US4247635 Microbiological reduction of 15-ketoprostaglandin intermediates
06/1980
06/25/1980	EP0012710A1 Microbiological reduction of 15-keto-prostaglandine intermediates
05/1980
05/27/1980	USRE30287 19 Hydroxy prostaglandins
02/1980
02/26/1980	US4190670 Prostaglandin derivatives
08/1979
08/14/1979	US4164446 Prostaglandin derivatives
07/1979
07/31/1979	US4163108 Anticoagulants
12/1978
12/26/1978	CA1045131A1 Derivatives of 9-hydroxy-13-trans-prostenoic acid
09/1978
09/26/1978	CA1039277A1 (d1)-13-substituted sulfinyl-prostaglandin-like compounds and methods of making
09/12/1978	CA1038378A1 13-cis prostaglandin derivatives and methods of making
10/1977
10/18/1977	US4054595 18 OR 19 Hydroxy prostaglandins
07/1977
07/19/1977	US4036876 Hypotensive, bronchodilators, labor inducers
04/1977
04/19/1977	US4018812 16-methylene-prostaglandin compounds
02/1977
02/15/1977	US4008263 Racemic fluoro-substituted PGF2 .sub.α analogs
11/1976
11/23/1976	US3993687 Antiulcer, inhibition of platelet aggregation
10/1976
10/26/1976	US3988361 8β-PGE2 and related compounds
10/19/1976	US3987083 Racemic prostaglandins of the 2-series and analogs thereof
09/1976
09/28/1976	US3983155 Racemic prostaglandins of the 2-series and analogs thereof
09/28/1976	US3983154 Racemic prostaglandins of the 2-series and analogs thereof
09/28/1976	US3983153 Prostaglandins
09/14/1976	US3980691 Antiulcer, inhibition of platelet aggression, increase of nasal patency, abortion, wound healing
08/1976
08/10/1976	US3974200 Racemic prostaglandins of the 2-series and analogs thereof
07/1976
07/20/1976	US3970685 (DL)-13-Substituted sulfinyl-prostaglandin-like compounds
05/1976
05/25/1976	US3959346 Racemic prostaglandins of the 2-series and analogs thereof
04/1976
04/27/1976	US3953495 16-Methylene PGE2
04/13/1976	US3950406 Hydroxylated 15-deoxy derivatives of 9-hydroxy-13-trans-prostenoic acid
01/1976
01/06/1976	US3931282 11α-Hydroxymethyl prostaglandins
01/06/1976	US3930952 Microbiological reduction of PGA2 and 15-epi PGA2